SK Group is considering business adjustments in the pharmaceutical and bio sectors. This is to streamline overlapping businesses and secure liquidity for future business investments.
According to the pharmaceutical industry on the 25th, SK Inc.'s pharmaceutical contract development and manufacturing organization (CDMO) subsidiary SK Pharmteco is reportedly in discussions to sell its manufacturing plant in Virginia, one of three pharmaceutical manufacturing facilities in the United States, to the global pharmaceutical company Novo Nordisk. Novo Nordisk is a Danish company famous for its obesity treatment drug, Wegovy.
Recently, Novo Nordisk announced plans to invest $4.1 billion (approximately 5.7 trillion KRW) to build a new production facility in Clayton, North Carolina.
SK Pharmteco's Virginia plant is a raw material pharmaceutical manufacturing plant focused on synthetic drugs. The site covers 600,000㎡ with a production capacity of 188㎥.
Industry insiders speculate that SK Pharmteco may be aiming to focus more on biopharmaceuticals rather than synthetic drugs through this sale. SK Inc. stated that the Virginia plant is a small-scale synthetic drug plant and not a core bio plant, and that nothing has been finalized, including the decision on the sale.
Meanwhile, SK Pharmteco acquired the French cell and gene therapy (CGT) CDMO company Eposkesi in 2021 and the U.S. CGT CDMO company CBM last year.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
